Search results for "HOMA"

showing 10 items of 956 documents

Cryptic Insertions Of The Immunoglobulin Light Chain Enhancer Region Near CCND1 In T(11;14)-Negative Mantle Cell Lymphoma

2019

Cyclin D1+ mantle cell lymphoma (MCL) is molecularly characterized by the t(11;14)(q13;q32) or rearrangements of CCND1 gene with the immunoglobulin (IG) light chains.1,2 Most MCL can be diagnosed based on the characteristic pathologic features and cyclin D1 expression without the need for demonstrating the genetic translocation. However, in cases with atypical morphologic or phenotypic features other B-cell neoplasms that sometimes also have cyclin D1 positivity may be in the differential diagnosis.1 In these situations the detection of the CCND1 rearrangements may assist in the diagnosis since most other lymphomas do not carry translocations of the gene.3-7 A subset of plasma cell myelomas…

MaleLimfomesHematologyLymphoma Mantle-CellMiddle AgedTranslocation GeneticMalaltia de Hodgkin03 medical and health sciencesMutagenesis Insertional0302 clinical medicinePolitical sciencehemic and lymphatic diseasesHumansCyclin D1Immunoglobulin Light ChainsLymphomasHodgkin's diseaseOnline Only ArticlesImmunoglobulinesHumanities030215 immunologyAged
researchProduct

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.

2011

The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasma(defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Method…

MaleLimfomesLymphomaDiseaseLymphoid neolasmas survival0302 clinical medicineEpidemiology80 and overRegistriesChildAged 80 and overLeukemialymphoid neoplasmsIncidenceRegistries/statistics & numerical dataAge FactorsHematologyMiddle Aged3. Good healthEuropeSurvival RateChild Preschool030220 oncology & carcinogenesisFemaleLymphomasLymphoid neolasmas survival; Europe.Adultmedicine.medical_specialtyAdult; Age Factors; Aged; Aged 80 and over; Child; Child Preschool; Europe; Female; Humans; Incidence; Infant; Infant Newborn; Leukemia; Lymphoma; Male; Middle Aged; Registries; Sex Factors; Survival Analysis; Survival Rate; Young AdultNOEurope/epidemiology03 medical and health sciencesYoung AdultSex FactorsInternal medicinemedicineHumansLeukemia/classification/epidemiology/mortalityCancer survival; lymphoid neoplasmsPreschoolSurvival rateSurvival analysisddc:613AgedTumorsbusiness.industryPublic healthInfant NewbornCancerInfantLymphoma/classification/epidemiology/mortalityOriginal Articlesmedicine.diseaseNewbornSurvival AnalysisCancer survivalSurgeryCancer registrybusinessInternational Classification of Diseases for Oncology030215 immunology
researchProduct

Correction: Association of ionizing radiation dose from common medical diagnostic procedures and lymphoma risk in the Epilymph case-control study

2020

International audience; Medical diagnostic X-rays are an important source of ionizing radiation (IR) exposure in the general population; however, it is unclear if the resulting low patient doses increase lymphoma risk. We examined the association between lifetime medical diagnostic X-ray dose and lymphoma risk, taking into account potential confounding factors, including medical history. The international Epilymph study (conducted in the Czech-Republic, France, Germany, Ireland, Italy, and Spain) collected self-reported information on common diagnostic X-ray procedures from 2,362 lymphoma cases and 2,465 frequency-matched (age, sex, country) controls. Individual lifetime cumulative bone mar…

MaleLimfomesLymphoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPhysiologyLogistic regressionPediatrics030218 nuclear medicine & medical imagingDiagnostic RadiologyHematologic Cancers and Related Disorders0302 clinical medicineRisk FactorsBone MarrowRadiation IonizingImmune PhysiologyOdds RatioMedicine and Health SciencesMedicineFamily historyCàncerCancerCancer risk factorseducation.field_of_studyMultidisciplinaryFactors de risc en les malaltiesRadiology and ImagingQConfoundingRHematologyMiddle AgedRadiation ExposureBone Imaging3. Good healthOncology030220 oncology & carcinogenesisMedicineFemaleLymphomasResearch ArticleAdultmedicine.medical_specialtyRisk factors in diseasesImaging TechniquesSciencePopulationImmunology[SDV.CAN]Life Sciences [q-bio]/CancerRadiation DosageResearch and Analysis Methods03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerRheumatologyDiagnostic MedicineInternal medicineOsteoarthritisCancer Detection and DiagnosisHumansMedical historyeducationAgedbusiness.industryArthritisCase-control studyCorrectionCancers and NeoplasmsBiology and Life SciencesOdds ratiomedicine.diseaseLymphomaX-Ray RadiographyMedical risk factorsLogistic Models[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control StudiesImmune System[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessPLoS ONE
researchProduct

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma

2003

The MALT1 gene was identified through its involvement in t(11;18)(q21;q21), seen in 30% of cases of mucosa-associated lymphoid tissue (MALT) lymphoma. Here, we show that deregulated MALT1 expression may occur in B-cell non-Hodgkin lymphoma (B-NHL) of various histologic subtypes either through translocation to the immunoglobulin heavy chain (IGH) locus or by genomic amplification. First, 2 cases, one case of MALT lymphoma and another of aggressive marginal zone lymphoma (MZL) with t(14;18)(q32;q21), cytogenetically identical to the translocation involving BCL2, were shown by fluorescence in situ hybridization (FISH) to involve MALT1, which lies about 5 Mb centromeric of BCL2. Molecular cloni…

MaleLymphoma B-CellImmunologyBiologyBiochemistryTranslocation Geneticimmune system diseaseshemic and lymphatic diseasesGene duplicationmedicineHumansRNA NeoplasmAgedChromosomes Human Pair 14medicine.diagnostic_testGene Expression ProfilingGene AmplificationMALT lymphomaLymphoma B-Cell Marginal ZoneCell BiologyHematologyMiddle Agedmedicine.diseaseMolecular biologyGenes bcl-2Neoplasm ProteinsGene Expression Regulation NeoplasticGene expression profilingMALT1Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinCaspasesB-Cell Non-Hodgkin LymphomaImmunoglobulin heavy chainFemaleChromosomes Human Pair 18Comparative genomic hybridizationFluorescence in situ hybridizationBlood
researchProduct

Hypothyroidism in patients treated with radiotherapy for head and neck carcinoma: standardised long-term follow-up study

2016

AbstractObjective:Hypothyroidism is a common complication when radiotherapy is part of the treatment for head and neck tumours. This study aimed to show the incidence of hypothyroidism and possible risk factors in these patients.Methods:Factors related to the population, tumour, treatment and occurrence of hypothyroidism were analysed in 241 patients diagnosed with head and neck carcinoma.Results:Approximately 53 per cent of patients were diagnosed with radiation-induced hypothyroidism. Its occurrence was related to: tumour location, laryngeal surgery type, neck dissection type, post-operative complications, cervical radiotherapy and radiotherapy unit type (linear particle accelerator or te…

MaleLymphomamedicine.medical_treatmentPostoperative Complications0302 clinical medicineRisk FactorsProspective Studies030223 otorhinolaryngologyProspective cohort studyMelanomaHead And Neck Cancereducation.field_of_studyIncidenceThyroidGeneral MedicineMiddle AgedCarcinoma Adenoid CysticAbscessmedicine.anatomical_structureHead and Neck NeoplasmsLymphatic Metastasis030220 oncology & carcinogenesisCarcinoma Squamous CellNeck DissectionFemaleThyroid functionmedicine.medical_specialtyPopulationRadiation Therapy03 medical and health sciencesHypothyroidismSurgical Wound DehiscencemedicineHumansRadiation InjurieseducationAgedRadiotherapySquamous Cell Carcinoma of Head and Neckbusiness.industryHead and neck cancerNeck dissectionmedicine.diseaseSurgeryRadiation therapyLogistic ModelsOtorhinolaryngologySpainMultivariate AnalysisCarcinoma MucoepidermoidComplicationbusinessFollow-Up StudiesThe Journal of Laryngology & Otology
researchProduct

Total, red and processed meat consumption and human health: an umbrella review of observational studies

2022

Meat consumption has represented an important evolutionary step for humans. However, modern patterns of consumption, including excess intake, type of meat and cooking method have been the focus of attention as a potential cause of rise in non-communicable diseases. The aim of this study was to investigate the association between total, red and processed meat with health outcomes and to assess the level of evidence by performing a systematic search of meta-analyses of prospective cohort studies. Convincing evidence of the association between increased risk of (i) colorectal adenoma, lung cancer, CHD and stroke, (ii) colorectal adenoma, ovarian, prostate, renal and stomach cancers, CHD and st…

MaleMeatRANDOMIZED CONTROLLED-TRIALSprocessed foodsBLADDER-CANCERcolorectal cancerANIMAL SOURCE FOODSmeta-analysiESOPHAGEAL CANCER-RISKCOLORECTAL-CANCERprocessed foodcardiovascular diseaseRisk FactorsTotal meatBREAST-CANCERcancerHumansCookingProspective StudiesSettore MED/49 - Scienze Tecniche Dietetiche Applicatecoronary heart diseasenon-communicable diseaseprocessed meatumbrella reviewevidencefood and beveragesnon-communicable diseasesDietmeta-analysisStrokeObservational Studies as TopicRed MeatDOSE-RESPONSE METAANALYSISFATTY-ACIDSNON-HODGKIN-LYMPHOMAColorectal NeoplasmsDIETARY FACTORSFood ScienceInternational Journal of Food Sciences and Nutrition
researchProduct

[Bilateral testicular lymphoma. Case report]

2008

A case of bilateral testicular lymphoma with involvement of skin and oropharynx was described. After a review of literature, the Authors underline the clinical features focusing the diagnostic approaches and the therapeutics options.

MaleNeoplasms Multiple PrimaryLymphomaTesticular NeoplasmsHumanstesticular lymphomaMiddle Aged
researchProduct

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma

2015

Objective: This is the final report of a phase III randomized study to evaluate whole-brain radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median follow-up of 81.2 months. Methods: Patients with newly diagnosed PCNSL were randomized to high-dose methotrexate (HDMTX)–based chemotherapy alone or followed by WBRT. We hypothesized that the omission of WBRT would not compromise overall survival (OS; primary endpoint), using a noninferiority design with a margin of 0.9. Results: In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18.2 vs 11.9 months, hazard ratio [HR] 0.83 [95% confidence interval (CI) 0…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyLymphomamedicine.medical_treatmentPopulationMedizin610 Medicine & healthDisease-Free Survivallaw.inventionCentral Nervous System NeoplasmsRandomized controlled triallawInternal medicinemedicineClinical endpointHumanseducationAgededucation.field_of_studyChemotherapybusiness.industryHazard ratioAntineoplastic ProtocolsMiddle AgedCombined Modality TherapyConfidence interval10040 Clinic for NeurologyRadiation therapyMethotrexateTreatment Outcome2728 Neurology (clinical)MethotrexateNeurology (clinical)Cranial Irradiationbusinessmedicine.drug
researchProduct

Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematolo…

2013

Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and …

MaleOncologyCancer ResearchIndolesMyeloidhodgkin lymphomahydroxamic acidAdministration Oralresponse criteriaPharmacologyHydroxamic Acidst-cell lymphomaHistoneschemistry.chemical_compoundhemic and lymphatic diseasesAged 80 and overHematologyMiddle AgedLeukemiaTreatment Outcomemedicine.anatomical_structuremyelomaOncologyvorinostatHematologic NeoplasmsFemaleAdultmedicine.medical_specialtypanobinostatrefractory multiple-myelomaMaximum Tolerated DoseAntineoplastic AgentsmyelofibrosisNeutropeniahistone deacetylase inhibitorsmyelodysplastic disordersDrug Administration ScheduleYoung AdultInternal medicinePanobinostatmedicineHumansIn patientAdverse effectMyelofibrosisAgedNeoplasm Staginginternational-working-groupacetylationbusiness.industrymedicine.diseaseLymphomachemistryhistone deacetylasehypoxia-inducible factor-1-alphalbh589business
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct